Literature DB >> 8104554

Dopamine receptor pharmacology.

P Seeman1, H H Van Tol.   

Abstract

Although antipsychotic drugs originally helped to discover dopamine receptors, the five dopamine receptors presently identified and cloned are facilitating the search for and discovery of more selective antipsychotic and antiparkinson drugs. The D1-like dopamine receptors, D1 and D5, are sensitive to the same drugs as the D1 receptor in native tissues, but D5 is about 10 times more sensitive to dopamine than D1. The D2-like receptors, D2, D3, and D4, have approximately similar sensitivities to dopamine, but bromocriptine and raclopride are both about two orders of magnitude weaker at D4, whereas clozapine is one order more potent at D4, as compared with D2 and D3. The human dopamine D4 receptor has many variants. The sensitivities to clozapine of human variants D4.2, D4.4, and D4.7 are approximately similar, with dissociation constants between 5 and 24 nM, matching the spinal fluid concentration of clozapine under therapeutic conditions. Thus antipsychotic action may be effected through blockade of either dopamine D2 or D4 receptors.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8104554

Source DB:  PubMed          Journal:  Curr Opin Neurol Neurosurg        ISSN: 0951-7383


  18 in total

Review 1.  Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment.

Authors:  Christine Konradi; Stephan Heckers
Journal:  Pharmacol Ther       Date:  2003-02       Impact factor: 12.310

2.  Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial.

Authors:  C M Beasley; T Sanger; W Satterlee; G Tollefson; P Tran; S Hamilton
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

Review 3.  The role of dopamine-dependent negative feedback in the hippocampus-basal ganglia-thalamus-hippocampus loop in the extinction of responses.

Authors:  I G Sil'kis
Journal:  Neurosci Behav Physiol       Date:  2008-05

4.  Molecular components of striatal plasticity: the various routes of cyclic AMP pathways.

Authors:  A Rajadhyaksha; J Leveque; W Macías; A Barczak; C Konradi
Journal:  Dev Neurosci       Date:  1998       Impact factor: 2.984

5.  Aggression, DRD1 polymorphism, and lesion location in penetrating traumatic brain injury.

Authors:  Matteo Pardini; Frank Krueger; Colin A Hodgkinson; Vanessa Raymont; Maren Strenziok; Mario Amore; Eric M Wassermann; David Goldman; Jordan H Grafman
Journal:  CNS Spectr       Date:  2014-03-11       Impact factor: 3.790

6.  Working memory span capacity improved by a D2 but not D1 receptor family agonist.

Authors:  Isadore S Tarantino; Richard F Sharp; Mark A Geyer; Jessica M Meves; Jared W Young
Journal:  Behav Brain Res       Date:  2011-01-11       Impact factor: 3.332

Review 7.  The importance of dopamine D4 receptors in the action and development of antipsychotic agents.

Authors:  G P Reynolds
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

Review 8.  Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses.

Authors:  R B Belgamwar; M Fenton
Journal:  Cochrane Database Syst Rev       Date:  2005-04-18

9.  Effect of apomorphine on cognitive performance and sensorimotor gating in humans.

Authors:  Arnt F A Schellekens; K P Grootens; C Neef; Kris L L Movig; J K Buitelaar; B Ellenbroek; R J Verkes
Journal:  Psychopharmacology (Berl)       Date:  2009-10-16       Impact factor: 4.530

10.  Time course of bromocriptine induced excitation in the rat: behavioural and biochemical studies.

Authors:  D M Jackson; N Mohell; J Georgiev; A Bengtsson; L G Larsson; O Magnusson; S B Ross
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-02       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.